ClinicalTrials.gg
CompletedNCT02336347Updated Apr 28, 2026

A Phase 1 Study Comparing AVP-786 With AVP-923

A Phase 1 interventional study of AVP-786 and AVP-923 in Healthy Volunteer, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled May 2014, registered Jan 2015).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

To compare pharmacokinetics (PK) of AVP-786 (deuterated [d6] dextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) to AVP-923 (dextromethorphan hydrobromide [DM]/Q) at steady state.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Pharmacokinetics
  • Healthy Volunteers
  • deuterated dextromethorphan
  • deuterated dextromethorphan with quinidine
03

In context

Lead sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.

Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult males or females
  • 18 - 60 years of age
  • 18 - 32 kg/m2

Exclusion criteria

Exclusion Criteria:

  • History or presence of significant disease
  • History of substance abuse and/or alcohol abuse with the past 2 years
  • Use of tobacco-containing or nicotine-containing products within 6 months
  • Use of any prescription or the over-the-counter medications within 14 days
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Group 1 - Period 1

    Twice daily dosing of AVP-786 orally for 8 days

    Drug: AVP-786

  • Active comparator
    Group 1 - Period 2

    Twice daily dosing of AVP-923 orally for 8 days

    Drug: AVP-923

  • Active comparator
    Group 2 - Period 1

    Twice daily dosing of AVP-923 orally for 8 days

    Drug: AVP-923

  • Experimental
    Group 2 - Period 2

    Twice daily dosing of AVP-786 orally for 8 days

    Drug: AVP-786

Interventions

06

What researchers measure

Primary outcomes

  1. PK of d6-DM in AVP-786 compared to DM in AVP-923

    Time frame: 8 days

Secondary outcomes

  1. PK of metabolites

    Time frame: 8 days

  2. Safety and tolerability

    Time frame: 8 days

07

Study locations

1 site
  • Covance Dallas Clinical Research Unit
    Dallas, Texas 75247, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2014 to primary completion in Sep 2014, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2015
First posted
Jan 13, 2015
StartActual
May 1, 2014
Primary completionActual
Sep 1, 2014
CompletionActual
Mar 1, 2015
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02336347
Responsible party
Sponsor
First posted
Jan 13, 2015
Start date
May 1, 2014
Primary completion
Sep 1, 2014
Completion
Mar 1, 2015
Last update
Apr 28, 2026

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Deudextromethorphan · Quinidine

Start the discussion